Author of

• 18973

  +

  P2.01 - Advanced NSCLC (ID 618)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)

  • 23174

    +

    P2.01-051 - Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic /Locally Advanced EGFR Mutation Negative NSCLC (ID 10362)

    09:00 - 09:00  |  Author(s): S. Shah
    • Abstract

    Background:
    Maintenance treatment of locally advanced or metastatic non small cell lung cancer ( NSCLC ) other than predominantly Squamous cell histology in patients whose disease has not progressed following 4 to 6 cycles of platinum based doublet therapy has been standard of care . Pemetrexed and Erlotinib both have been used as either continuous maintenance or switch maintenance therapy.
    
    Method:
    All patients of NSCLC other than the Squamous cell carcinoma , who have completed either 4 or 6 cycles of platinum and pemetrexed and have either CR /PR/SD on response assessment scan post induction treatment and willing to participate in study ,were randomized to receive either pemetrexed or erlotinib . Quality of life (QoL) questioners were collected every 8 weeks till disease progression or unacceptable toxicities. Patients were followed up till death. PFS and OS were calculated for each arm and indirectly compared.
    
    Result:
    Two hundred patients were randomized to receive either pemetrexed or erlotinib) from November 2014 to March 2017. Median age of cohort was 55 (28-79).One hundred and thirty two patients were male and 68 were female. PS was 0-1 in 195 patients. Sixty three percent were smokers (126/200). Majority of patients (62.5 %) has stable disease post completion of induction chemotherapy (125 /200).Median number of cycle of maintenance pemetrexed was 4 (4-6). Median PFS in pemetrexed arm was 4.46 month ( 95 % confidence interval (CI); 3.98 to 4.95 ) while in erlotinib arm median PFS was 4.5 month ( 95 % CI ; 3.98 to 4.95),( hazard ratio , 0.98 ; 95% CI , 0.714 to 1.369 , p value 0.945).Median OS from starting induction chemotherapy in pemetrexed arm was 16.56 months ( 95 % CI ; 14.83 to 18.29 ) while in erlotinib arm median OS was 18.33 months ( 95% CI ; 13.74 to 22.92),(hazard ratio , 1.23 ; ( 95 % CI ; 0.829 to 1.831 , p value 0.0302)
    
    Conclusion:
    Maintenance treatment with pemetrexed and erlotinib has similar PFS and OS in indirect comparison. QoL analysis in both arms is ongoing.